查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1813899

美国神经病学临床试验市场规模、份额和趋势分析报告：按阶段、研究设计、适应症、价值炼和细分市场预测，2025-2033 年

U.S. Neurology Clinical Trials Market Size, Share & Trends Analysis Report By Phase, By Study Design, By Indication, By Indication by Study Design, By Indication by Phase, By Value Chain, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

美国神经病学临床试验市场摘要

预计 2024 年美国神经病学临床试验市场价值将达到 25.3 亿美元，到 2033 年将达到 44.7 亿美元，2025 年至 2033 年的复合年增长率为 6.59%。

美国神经病学临床试验市场的成长受到神经科学的重大进步、医疗保健支出的增加以及对复杂神经系统疾病的标靶治疗的重视的推动。

推动美国神经病学临床试验产业成长的其他因素包括患者意识的提升、对孤儿药和突破性疗法的监管支持，以及对神经病学研发的投入不断增加。神经退化性疾病的日益流行，加上完善的临床研究基础设施，使美国成为神经病学临床试验的重要枢纽。此外，来自公共和私营部门的资金，以及製药公司、委外研发机构(CRO) 和学术机构之间的策略联盟，在加快试验进度和提高试验效率方面发挥关键作用，进一步支撑了市场发展。

阿兹海默症、帕金森氏症、多发性硬化症、癫痫和各种罕见神经系统综合症的盛行率不断上升，推动了对新型治疗方案的需求并增加了临床试验的数量。这些研究涵盖了早期到晚期阶段，更先进的项目专注于疾病修正治疗、神经保护剂和基于基因的干预。此外，製药和生物技术公司正在扩展其内部 CRO 能力，以管理临床试验通讯协定、加快执行速度并简化临床试验操作。而且，以神经病学为重点的临床实验地点的数量正在增加，从而提高了患者招募的准确性、优化了临床实验品质并缩短了入组时间。内部能力和地点专业知识的结合正在提高该国神经病学临床试验的规模和实施率。

此外，市场参与企业正转向采用分散式和混合式临床试验模式，以实现更广泛的患者参与和更快的数据收集。此外，先进神经影像技术、基于生物标记的诊断方法以及人工智慧主导的患者选择工具的日益普及，正在提高试验的准确性和结果的可预测性。此外，许多生物製药公司正在扩展其神经病学研究组合和站点网络，以扩大其地理覆盖范围，加快监管核准，并更好地满足医疗资源匮乏地区患者的未满足需求，从而进一步推动美国神经病学临床试验市场的发展。

因此，神经病学临床试验市场对美国医疗保健产业至关重要，因为它能够解决对医疗成本、劳动生产力和患者整体生活品质产生重大影响的病症。此外，这些临床试验对于将科学创新转化为可销售的治疗方法，同时减轻疾病负担至关重要。预计上述因素将在预计的时间内推动市场发展。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国神经病学临床试验市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/辅助市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 市场挑战
    • 市场机会
  • 研发成本分析（2021-2024）
  • 技术格局
  • 定价模式分析
  • 2024年临床试验量分析
    • 2024年美国神经学临床试验（分阶段）总数
    • 2024 年美国神经病学临床试验总数（依研究设计）
    • 2024 年美国神经病学临床试验总数（按主要适应症划分）
  • 关税影响分析
  • 价值链分析
    • 供应趋势
    • 需求趋势
  • 市场分析工具
    • 波特五力分析
    • PESTEL 与 SWOT 分析

第四章美国神经病学临床试验市场：阶段估计与趋势分析

  • 美国神经病学临床试验市场（按阶段）：细分仪表板
  • 美国神经病学临床试验市场（分阶段）：波动分析
  • 阶段，2021-2033
  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

第五章美国神经病学临床试验市场：试验设计评估与趋势分析

  • 美国神经病学临床试验市场（依研究设计）：细分仪表板
  • 美国神经病学临床试验市场（依研究设计）：变异分析
  • 按研究设计，2021-2033年
  • 侵入性
  • 观察
  • 扩展访问

第六章：美国神经病学临床试验市场：适应症估计与趋势分析

  • 美国神经病学临床试验市场（按适应症）：细分仪表板
  • 美国神经病学临床试验市场（按适应症）：差异分析
  • 依症状，2021-2033 年
  • 阿兹海默症
  • 忧郁症（MDD）
  • 帕金森氏症（PD）
  • 癫痫
  • 中风
  • 创伤性脑损伤（TBI）
  • 肌萎缩侧索硬化症（ALS）
  • 亨丁顿舞蹈症
  • 肌肉再生
  • 其他的

第七章美国神经病学临床试验市场：依研究设计适应症的估计与趋势分析

  • 美国神经病学临床试验市场，按研究设计分类的适应症：细分仪表板
  • 美国神经病学临床试验市场，依研究设计分類的适应症：变异分析
  • 按研究设计，2021-2033年
  • 阿兹海默症
    • 阿兹海默症干预
    • 阿兹海默症观察
    • 阿兹海默症扩大可及性
  • 忧郁症（MDD）
    • 忧郁症（MDD）干预
    • 忧郁症（MDD）观察
    • 扩大忧郁症治疗途径（MDD）
  • 帕金森氏症（PD）
    • 帕金森氏症 (PD) 干预
    • 帕金森氏症（PD）观察
    • 帕金森氏症 (PD) 扩展获取途径
  • 癫痫
    • 癫痫干预
    • 癫痫观察
    • 癫痫扩展准入
  • 中风
    • 中风干预
    • 中风观察
    • 中风扩展访问
  • 创伤性脑损伤（TBI）
    • 创伤性脑损伤 (TBI) 干预
    • 创伤性脑损伤（TBI）观察
    • 创伤性脑损伤 (TBI) 扩展访问
  • 肌萎缩侧索硬化症（ALS）
    • 肌萎缩侧索硬化症（ALS）干预
    • 肌萎缩侧索硬化症（ALS）观察性研究
    • 肌萎缩侧索硬化症（ALS）扩展获取途径
  • 亨丁顿舞蹈症
    • 亨丁顿舞蹈症干预
    • 亨丁顿舞蹈症观察
    • 扩大亨廷顿舞蹈症的治疗范围
  • 肌肉再生
    • 肌肉再生干预
    • 肌肉再生观察
    • 扩大肌肉再生途径
  • 其他的
    • 其他干预措施
    • 其他观察
    • 其他扩展访问

第 8 章：美国神经病学临床试验市场：适应症估计与各阶段趋势分析

  • 美国神经病学临床试验市场（按适应症和阶段）：细分仪表板
  • 美国神经病学临床试验市场（按适应症和阶段）：差异分析
  • 阶段，2021-2033
  • 阿兹海默症
    • 阿兹海默症第一阶段
    • 阿兹海默症2期
    • 阿兹海默症III 期
    • 阿兹海默症IV 期
  • 忧郁症（MDD）
    • 忧郁症（MDD）第一阶段
    • 忧郁症（MDD）第二阶段
    • 忧郁症（MDD）III期
    • 忧郁症（MDD）IV期
  • 帕金森氏症（PD）
    • 帕金森氏症（PD）I期
    • 帕金森氏症 (PD) II 期试验
    • 帕金森氏症 (PD) III 期试验
    • 帕金森氏症 (PD) IV 期试验
  • 癫痫
    • 癫痫1期
    • 癫痫2期
    • 癫痫3期
    • 癫痫IV期
  • 中风
    • 中风第一期
    • 中风 II 期
    • 中风 III 期
    • 中风IV期
  • 创伤性脑损伤（TBI）
    • 创伤性脑损伤 (TBI) 第一期
    • 创伤性脑损伤（TBI）II期
    • 创伤性脑损伤（TBI）III期
    • 创伤性脑损伤（TBI）IV期
  • 肌萎缩侧索硬化症（ALS）
    • 肌萎缩侧索硬化症（ALS）I期
    • 肌萎缩侧索硬化症（ALS）II期
    • 肌萎缩侧索硬化症（ALS）3期临床试验
    • 肌萎缩侧索硬化症（ALS）IV期试验
  • 亨丁顿舞蹈症
    • 亨廷顿舞蹈症的分期
    • 亨廷顿氏舞蹈症 II 期
    • 亨丁顿舞蹈症 III 期
    • 亨廷顿氏舞蹈症IV期
  • 肌肉再生
    • 肌肉再生第一阶段
    • 肌肉再生第二阶段
    • 肌肉再生第三阶段
    • 肌肉再生第四阶段
  • 其他的
    • 其他第一阶段
    • 其他第二阶段
    • 其他第三期
    • 其他 IV 期

第九章美国神经病学临床试验市场：价值链评估与趋势分析

  • 美国神经病学临床试验市场价值链：细分仪表板
  • 美国神经病学临床试验市场（价值链）：变化分析
  • 按价值链划分，2021-2033年
  • 内部
  • CRO
  • 临床实验试验地点/临床地点

第十章 竞争格局

  • 市场参与企业分类
    • 市场领导
    • 新兴企业
  • 2024年市场估值分析（热图分析）
  • 公司简介
    • Syneos Health
    • Icon Plc
    • Lindus Health
    • AbbVie
    • GlaxoSmithKline
    • Labcorp Drug Development
    • Pfizer
    • AstraZeneca
    • Biogen
    • Eli Lilly
    • Alzheon
    • BDD Pharma
Product Code: GVR-4-68040-714-9

U.S. Neurology Clinical Trials Market Summary

The U.S. neurology clinical trials market size was estimated at USD 2.53 billion in 2024 and is projected to reach USD 4.47 billion by 2033, growing at a CAGR of 6.59% from 2025 to 2033. The growth of the U.S. market for neurology clinical trials is driven by significant advancements in neuroscience, increasing healthcare spending, and an emphasis on targeted therapies for intricate neurological conditions.

Other factors driving the growth of the U.S. neurology clinical trials industry include increasing patient awareness, regulatory support for orphan drugs and breakthrough therapies, and rising investment in neurology research and development. The rising incidence of neurodegenerative diseases, supported by a well-established clinical research infrastructure, has established the U.S. as a key center for neurology trials. Furthermore, funding from both public and private sectors and strategic partnerships among pharmaceutical companies, contract research organizations (CROs), and academic institutions have played a crucial role in speeding up study timelines and enhancing trial efficiency, further supporting the market.

The increasing prevalence of Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, and various rare neurological syndromes has created an increased need for novel treatment options, resulting in a rise in the number of clinical trial activities. These studies are conducted in early and late stages, with more advanced programs concentrating on disease-modifying therapies, neuroprotective agents, and gene-based interventions. In addition, pharmaceutical and biotechnology companies are expanding in-house CRO capabilities to maintain control over study protocols, enhance execution speed, and increase operational efficiency for clinical trials. Besides, a growing number of investigator sites specializing in neurology are further improving patient recruitment accuracy, optimizing trial quality, and shortening enrollment timelines. This blend of in-house capabilities and specialized site expertise boosts the scale and rate of neurological trial delivery across the country.

Moreover, market trends are shifting towards adopting decentralized and hybrid trial models, allowing for broader patient participation and faster data collection. Further, the growing incorporation of advanced neuroimaging techniques, biomarker-based diagnostics, and AI-driven patient selection tools is enhancing the precision of trials and the predictability of outcomes. Furthermore, numerous biopharmaceutical companies are expanding their neurology research portfolios and site networks to strengthen their geographic reach, accelerate regulatory approvals, and better address the unmet needs of patients in underserved areas, further supporting the U.S. neurology clinical trials market.

Thus, the neurology clinical trials market is crucial to the U.S. healthcare industry, as it tackles conditions that heavily influence healthcare costs, workforce productivity, and patients' overall quality of life. Besides, these trials are essential for converting scientific innovations into market-ready treatments while reducing disease burden. Such aforementioned factors are expected to drive the market over the estimated timeframe.

U.S. Neurology Clinical Trials Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. neurology clinical trials market report based onphase, study design, indication, indication by study design, indication by phase, and value chain:

  • Phase Outlook (Revenue, USD Million, 2021 - 2033)
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
  • Study Design Outlook (Revenue, USD Million, 2021 - 2033)
  • Interventional
  • Observational
  • Expanded Access
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Alzheimer's Disease
  • Depression (MDD)
  • Parkinson's Disease (PD)
  • Epilepsy
  • Stroke
  • Traumatic Brain Injury (TBI)
  • Amyotrophic Lateral Sclerosis (ALS)
  • Huntington's Disease
  • Muscle Regeneration
  • Others
  • Indication by Study Design Outlook (Revenue, USD Million, 2021 - 2033)
  • Alzheimer's Disease
    • Interventional
    • Observational
    • Expanded Access
  • Depression (MDD)
    • Interventional
    • Observational
    • Expanded Access
  • Parkinson's Disease (PD)
    • Interventional
    • Observational
    • Expanded Access
  • Epilepsy
    • Interventional
    • Observational
    • Expanded Access
  • Stroke
    • Interventional
    • Observational
    • Expanded Access
  • Traumatic Brain Injury (TBI)
    • Interventional
    • Observational
    • Expanded Access
  • Amyotrophic Lateral Sclerosis (ALS)
    • Interventional
    • Observational
    • Expanded Access
  • Huntington's Disease
    • Interventional
    • Observational
    • Expanded Access
  • Muscle Regeneration
    • Interventional
    • Observational
    • Expanded Access
  • Others
    • Interventional
    • Observational
    • Expanded Access
  • Indication by Phase Outlook (Revenue, USD Million, 2021 - 2033)
  • Alzheimer's Disease
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Depression (MDD)
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Parkinson's Disease (PD)
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Epilepsy
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Stroke
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Traumatic Brain Injury (TBI)
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Amyotrophic Lateral Sclerosis (ALS)
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Huntington's Disease
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Muscle Regeneration
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Others
    • Phase I
    • Phase II
    • Phase III
    • Phase IV
  • Value Chain Outlook (Revenue, USD Million, 2021 - 2033)
  • In-house
  • CROs
  • Investigator Sites/ Clinical Sites

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Study Design
    • 1.2.2. Indication
    • 1.2.3. Indication by Study Design
    • 1.2.4. Indication by Phase
    • 1.2.5. Value Chain
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Parent Market Analysis
    • 1.7.3. Bottom-Up Analysis
    • 1.7.4. Multivariate Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Neurology Clinical Trials Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of neurological diseases such as Alzheimer's disease, epilepsy, and stroke
      • 3.2.1.2. Growing adoption of novel technologies in clinical research
      • 3.2.1.3. Rising number of CROs providing U.S. Neurology Clinical research services
      • 3.2.1.4. Increasing funding for neurological studies by public organizations
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Increased associated with U.S. Neurology Clinical studies
      • 3.2.2.2. High failure rate coupled with patient dropout issues associated with neurological clinical trials
    • 3.2.3. Market Challenges
    • 3.2.4. Market Opportunities
  • 3.3. R&D Spending Analysis (2021-2024)
  • 3.4. Technology Landscape
  • 3.5. Pricing Model Analysis
  • 3.6. Clinical Trial Volume Analysis, 2024
    • 3.6.1. Total Number of U.S. Neurology Clinical Trials, by Phase, 2024
    • 3.6.2. Total Number of U.S. Neurology Clinical Trials, by Study Design, 2024
    • 3.6.3. Total Number of U.S. Neurology Clinical Trials, by Key Indication, 2024
  • 3.7. Tariff Impact Analysis
  • 3.8. Value Chain Analysis
    • 3.8.1. Supply Trends
    • 3.8.2. Demand Trends
  • 3.9. Market Analysis Tools
    • 3.9.1. Porter's Five Forces Analysis
    • 3.9.2. PESTEL by SWOT Analysis

Chapter 4. U.S. Neurology Clinical Trials Market: Phase Estimates & Trend Analysis

  • 4.1. U.S. Neurology Clinical Trials Market, By Phase: Segment Dashboard
  • 4.2. U.S. Neurology Clinical Trials Market, By Phase: Movement Analysis
  • 4.3. U.S. Neurology Clinical Trials Market Estimates & Forecasts, By Phase, 2021 - 2033 (USD Million)
  • 4.4. Phase I
    • 4.4.1. Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Phase II
    • 4.5.1. Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Phase III
    • 4.6.1. Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Phase IV
    • 4.7.1. Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Neurology Clinical Trials Market: Study Design Estimates & Trend Analysis

  • 5.1. U.S. Neurology Clinical Trials Market, By Study Design: Segment Dashboard
  • 5.2. U.S. Neurology Clinical Trials Market, By Study Design: Movement Analysis
  • 5.3. U.S. Neurology Clinical Trials Market Estimates & Forecasts, By Study Design, 2021 - 2033 (USD Million)
  • 5.4. Interventional
    • 5.4.1. Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Observational
    • 5.5.1. Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Expanded Access
    • 5.6.1. Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Neurology Clinical Trials Market: Indication Estimates & Trend Analysis

  • 6.1. U.S. Neurology Clinical Trials Market, By Indication: Segment Dashboard
  • 6.2. U.S. Neurology Clinical Trials Market, By Indication: Movement Analysis
  • 6.3. U.S. Neurology Clinical Trials Market Estimates & Forecasts, By Indication, 2021 - 2033 (USD Million)
  • 6.4. Alzheimer's Disease
    • 6.4.1. Alzheimer's Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Depression (MDD)
    • 6.5.1. Depression (MDD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Parkinson's Disease (PD)
    • 6.6.1. Parkinson's Disease (PD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Epilepsy
    • 6.7.1. Epilepsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Stroke
    • 6.8.1. Stroke Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.9. Traumatic Brain Injury (TBI)
    • 6.9.1. Traumatic Brain Injury (TBI) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.10. Amyotrophic Lateral Sclerosis (ALS)
    • 6.10.1. Amyotrophic Lateral Sclerosis (ALS) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.11. Huntington's Disease
    • 6.11.1. Huntington's Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.12. Muscle Regeneration
    • 6.12.1. Muscle Regeneration Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.13. Others
    • 6.13.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Neurology Clinical Trials Market: Indication by Study Design Estimates & Trend Analysis

  • 7.1. U.S. Neurology Clinical Trials Market, Indication by Study Design: Segment Dashboard
  • 7.2. U.S. Neurology Clinical Trials Market, Indication by Study Design: Movement Analysis
  • 7.3. U.S. Neurology Clinical Trials Market Estimates & Forecasts, Indication by Study Design, 2021 - 2033 (USD Million)
  • 7.4. Alzheimer's Disease
    • 7.4.1. Alzheimer's Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. Alzheimer's Disease Interventional
      • 7.4.2.1. Alzheimer's Disease Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Alzheimer's Disease Observational
      • 7.4.3.1. Alzheimer's Disease Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Alzheimer's Disease Expanded Access
      • 7.4.4.1. Alzheimer's Disease Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Depression (MDD)
    • 7.5.1. Depression (MDD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. Depression (MDD) Interventional
      • 7.5.2.1. Depression (MDD) Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Depression (MDD) Observational
      • 7.5.3.1. Depression (MDD) Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. Depression (MDD) Expanded Access
      • 7.5.4.1. Depression (MDD) Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Parkinson's Disease (PD)
    • 7.6.1. Parkinson's Disease (PD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Parkinson's Disease (PD) Interventional
      • 7.6.2.1. Parkinson's Disease (PD) Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. Parkinson's Disease (PD) Observational
      • 7.6.3.1. Parkinson's Disease (PD) Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. Parkinson's Disease (PD) Expanded Access
      • 7.6.4.1. Parkinson's Disease (PD) Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Epilepsy
    • 7.7.1. Epilepsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Epilepsy Interventional
      • 7.7.2.1. Epilepsy Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Epilepsy Observational
      • 7.7.3.1. Epilepsy Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.4. Epilepsy Expanded Access
      • 7.7.4.1. Epilepsy Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Stroke
    • 7.8.1. Stroke Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. Stroke Interventional
      • 7.8.2.1. Stroke Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Stroke Observational
      • 7.8.3.1. Stroke Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. Stroke Expanded Access
      • 7.8.4.1. Stroke Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.9. Traumatic Brain Injury (TBI)
    • 7.9.1. Traumatic Brain Injury (TBI) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.9.2. Traumatic Brain Injury (TBI) Interventional
      • 7.9.2.1. Traumatic Brain Injury (TBI) Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.9.3. Traumatic Brain Injury (TBI) Observational
      • 7.9.3.1. Traumatic Brain Injury (TBI) Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.9.4. Traumatic Brain Injury (TBI) Expanded Access
      • 7.9.4.1. Traumatic Brain Injury (TBI) Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.10. Amyotrophic Lateral Sclerosis (ALS)
    • 7.10.1. Amyotrophic Lateral Sclerosis (ALS) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.10.2. Amyotrophic Lateral Sclerosis (ALS) Interventional
      • 7.10.2.1. Amyotrophic Lateral Sclerosis (ALS) Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.10.3. Amyotrophic Lateral Sclerosis (ALS) Observational
      • 7.10.3.1. Amyotrophic Lateral Sclerosis (ALS) Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.10.4. Amyotrophic Lateral Sclerosis (ALS) Expanded Access
      • 7.10.4.1. Amyotrophic Lateral Sclerosis (ALS) Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.11. Huntington's Disease
    • 7.11.1. Huntington's Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.11.2. Huntington's Disease Interventional
      • 7.11.2.1. Huntington's Disease Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.11.3. Huntington's Disease Observational
      • 7.11.3.1. Huntington's Disease Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.11.4. Huntington's Disease Expanded Access
      • 7.11.4.1. Huntington's Disease Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.12. Muscle Regeneration
    • 7.12.1. Muscle Regeneration Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.12.2. Muscle Regeneration Interventional
      • 7.12.2.1. Muscle Regeneration Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.12.3. Muscle Regeneration Observational
      • 7.12.3.1. Muscle Regeneration Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.12.4. Muscle Regeneration Expanded Access
      • 7.12.4.1. Muscle Regeneration Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.13. Others
    • 7.13.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.13.2. Others Interventional
      • 7.13.2.1. Others Interventional Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.13.3. Others Observational
      • 7.13.3.1. Others Observational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.13.4. Others Expanded Access
      • 7.13.4.1. Others Expanded Access Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. U.S. Neurology Clinical Trials Market: Indication by Phase Estimates & Trend Analysis

  • 8.1. U.S. Neurology Clinical Trials Market, Indication by Phase: Segment Dashboard
  • 8.2. U.S. Neurology Clinical Trials Market, Indication by Phase: Movement Analysis
  • 8.3. U.S. Neurology Clinical Trials Market Estimates & Forecasts, Indication by Phase, 2021 - 2033 (USD Million)
  • 8.4. Alzheimer's Disease
    • 8.4.1. Alzheimer's Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.2. Alzheimer's Disease Phase I
      • 8.4.2.1. Alzheimer's Disease Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.3. Alzheimer's Disease Phase II
      • 8.4.3.1. Alzheimer's Disease Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.4. Alzheimer's Disease Phase III
      • 8.4.4.1. Alzheimer's Disease Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.4.5. Alzheimer's Disease Phase IV
      • 8.4.5.1. Alzheimer's Disease Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Depression (MDD)
    • 8.5.1. Depression (MDD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.2. Depression (MDD) Phase I
      • 8.5.2.1. Depression (MDD) Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.3. Depression (MDD) Phase II
      • 8.5.3.1. Depression (MDD) Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.4. Depression (MDD) Phase III
      • 8.5.4.1. Depression (MDD) Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.5.5. Depression (MDD) Phase IV
      • 8.5.5.1. Depression (MDD) Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Parkinson's Disease (PD)
    • 8.6.1. Parkinson's Disease (PD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.2. Parkinson's Disease (PD) Phase I
      • 8.6.2.1. Parkinson's Disease (PD) Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.3. Parkinson's Disease (PD) Phase II
      • 8.6.3.1. Parkinson's Disease (PD) Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.4. Parkinson's Disease (PD) Phase III
      • 8.6.4.1. Parkinson's Disease (PD) Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.6.5. Parkinson's Disease (PD) Phase IV
      • 8.6.5.1. Parkinson's Disease (PD) Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Epilepsy
    • 8.7.1. Epilepsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.2. Epilepsy Phase I
      • 8.7.2.1. Epilepsy Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.3. Epilepsy Phase II
      • 8.7.3.1. Epilepsy Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.4. Epilepsy Phase III
      • 8.7.4.1. Epilepsy Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.7.5. Epilepsy Phase IV
      • 8.7.5.1. Epilepsy Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8. Stroke
    • 8.8.1. Stroke Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.2. Stroke Phase I
      • 8.8.2.1. Stroke Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.3. Stroke Phase II
      • 8.8.3.1. Stroke Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.4. Stroke Phase III
      • 8.8.4.1. Stroke Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.8.5. Stroke Phase IV
      • 8.8.5.1. Stroke Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.9. Traumatic Brain Injury (TBI)
    • 8.9.1. Traumatic Brain Injury (TBI) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.9.2. Traumatic Brain Injury (TBI) Phase I
      • 8.9.2.1. Traumatic Brain Injury (TBI) Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.9.3. Traumatic Brain Injury (TBI) Phase II
      • 8.9.3.1. Traumatic Brain Injury (TBI) Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.9.4. Traumatic Brain Injury (TBI) Phase III
      • 8.9.4.1. Traumatic Brain Injury (TBI) Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.9.5. Traumatic Brain Injury (TBI) Phase IV
      • 8.9.5.1. Traumatic Brain Injury (TBI) Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.10. Amyotrophic Lateral Sclerosis (ALS)
    • 8.10.1. Amyotrophic Lateral Sclerosis (ALS) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.10.2. Amyotrophic Lateral Sclerosis (ALS) Phase I
      • 8.10.2.1. Amyotrophic Lateral Sclerosis (ALS) Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.10.3. Amyotrophic Lateral Sclerosis (ALS) Phase II
      • 8.10.3.1. Amyotrophic Lateral Sclerosis (ALS) Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.10.4. Amyotrophic Lateral Sclerosis (ALS) Phase III
      • 8.10.4.1. Amyotrophic Lateral Sclerosis (ALS) Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.10.5. Amyotrophic Lateral Sclerosis (ALS) Phase IV
      • 8.10.5.1. Amyotrophic Lateral Sclerosis (ALS) Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.11. Huntington's Disease
    • 8.11.1. Huntington's Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.11.2. Huntington's Disease Phase
      • 8.11.2.1. Huntington's Disease Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.11.3. Huntington's Disease Phase II
      • 8.11.3.1. Huntington's Disease Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.11.4. Huntington's Disease Phase III
      • 8.11.4.1. Huntington's Disease Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.11.5. Huntington's Disease Phase IV
      • 8.11.5.1. Huntington's Disease Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.12. Muscle Regeneration
    • 8.12.1. Muscle Regeneration Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.12.2. Muscle Regeneration Phase I
      • 8.12.2.1. Muscle Regeneration Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.12.3. Muscle Regeneration Phase II
      • 8.12.3.1. Muscle Regeneration Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.12.4. Muscle Regeneration Phase III
      • 8.12.4.1. Muscle Regeneration Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.12.5. Muscle Regeneration Phase IV
      • 8.12.5.1. Muscle Regeneration Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.13. Others
    • 8.13.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.13.2. Others Phase I
      • 8.13.2.1. Others Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.13.3. Others Phase II
      • 8.13.3.1. Others Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.13.4. Others Phase III
      • 8.13.4.1. Others Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 8.13.5. Others Phase IV
      • 8.13.5.1. Others Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. U.S. Neurology Clinical Trials Market: Value Chain Estimates & Trend Analysis

  • 9.1. U.S. Neurology Clinical Trials Market, By Value Chain: Segment Dashboard
  • 9.2. U.S. Neurology Clinical Trials Market, By Value Chain: Movement Analysis
  • 9.3. U.S. Neurology Clinical Trials Market Estimates & Forecasts, By Value Chain, 2021 - 2033 (USD Million)
  • 9.4. In-house
    • 9.4.1. In-house Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5. CROs
    • 9.5.1. CROs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6. Investigator Sites/Clinical Sites
    • 9.6.1. Investigator Sites/Clinical Sites Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Market Participant Categorization
    • 10.1.1. Market Leaders
    • 10.1.2. Emerging Players
  • 10.2. Market Assessment Analysis, 2024 (Heat Map Analysis)
  • 10.3. Company Profiles
    • 10.3.1. Syneos Health
      • 10.3.1.1. Company Overview
      • 10.3.1.2. Financial Performance
      • 10.3.1.3. Service Benchmarking
      • 10.3.1.4. Strategic Initiatives
    • 10.3.2. Icon Plc
      • 10.3.2.1. Company Overview
      • 10.3.2.2. Financial Performance
      • 10.3.2.3. Service Benchmarking
      • 10.3.2.4. Strategic Initiatives
    • 10.3.3. Lindus Health
      • 10.3.3.1. Company Overview
      • 10.3.3.2. Financial Performance
      • 10.3.3.3. Service Benchmarking
      • 10.3.3.4. Strategic Initiatives
    • 10.3.4. AbbVie
      • 10.3.4.1. Company Overview
      • 10.3.4.2. Financial Performance
      • 10.3.4.3. Service Benchmarking
      • 10.3.4.4. Strategic Initiatives
    • 10.3.5. GlaxoSmithKline
      • 10.3.5.1. Company Overview
      • 10.3.5.2. Financial Performance
      • 10.3.5.3. Service Benchmarking
      • 10.3.5.4. Strategic Initiatives
    • 10.3.6. Labcorp Drug Development
      • 10.3.6.1. Company Overview
      • 10.3.6.2. Financial Performance
      • 10.3.6.3. Service Benchmarking
      • 10.3.6.4. Strategic Initiatives
    • 10.3.7. Pfizer
      • 10.3.7.1. Company Overview
      • 10.3.7.2. Financial Performance
      • 10.3.7.3. Service Benchmarking
      • 10.3.7.4. Strategic Initiatives
    • 10.3.8. AstraZeneca
      • 10.3.8.1. Company Overview
      • 10.3.8.2. Financial Performance
      • 10.3.8.3. Service Benchmarking
      • 10.3.8.4. Strategic Initiatives
    • 10.3.9. Biogen
      • 10.3.9.1. Company Overview
      • 10.3.9.2. Financial Performance
      • 10.3.9.3. Service Benchmarking
      • 10.3.9.4. Strategic Initiatives
    • 10.3.10. Eli Lilly
      • 10.3.10.1. Company Overview
      • 10.3.10.2. Financial Performance
      • 10.3.10.3. Service Benchmarking
      • 10.3.10.4. Strategic Initiatives
    • 10.3.11. Alzheon
      • 10.3.11.1. Company Overview
      • 10.3.11.2. Financial Performance
      • 10.3.11.3. Service Benchmarking
      • 10.3.11.4. Strategic Initiatives
    • 10.3.12. BDD Pharma
      • 10.3.12.1. Company Overview
      • 10.3.12.2. Financial Performance
      • 10.3.12.3. Service Benchmarking
      • 10.3.12.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. Neurology Clinical Trials Market Estimates and Forecasts, by Phase, 2021 - 2033 (USD Million)
  • Table 4 U.S. Neurology Clinical Trials Market Estimates and Forecasts, by Study Design, 2021 - 2033 (USD Million)
  • Table 5 U.S. Neurology Clinical Trials Market Estimates and Forecasts, by Indication, 2021 - 2033 (USD Million)
  • Table 6 U.S. Neurology Clinical Trials Market Estimates and Forecasts, by Indication by Study Design, 2021 - 2033 (USD Million)
  • Table 7 U.S. Neurology Clinical Trials Market Estimates and Forecasts, by Indication by Phase, 2021 - 2033 (USD Million)
  • Table 8 U.S. Neurology Clinical Trials Market Estimates and Forecasts, by Value Chain, 2021 - 2033 (USD Million)"

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD model sizing & forecasting
  • Fig. 9 Bottom-up approach
  • Fig. 10 Market snapshot
  • Fig. 11 Segment snapshot 1
  • Fig. 12 Segment snapshot 2
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Parent market outlook, 2024 (USD Billion)
  • Fig. 15 Ancillary market outlook, 2024 (USD Billion)
  • Fig. 16 U.S. neurology clinical trials market dynamics
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 U.S. neurology clinical trials market: phase outlook and key takeaways
  • Fig. 20 U.S. neurology clinical trials market: phase movement analysis
  • Fig. 21 Phase I market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Phase II market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Phase III market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Phase IV market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 U.S. neurology clinical trials market: study design outlook and key takeaways
  • Fig. 26 U.S. neurology clinical trials market: study design movement analysis
  • Fig. 27 Interventional market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Observational market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Expanded access market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 U.S. neurology clinical trials market: indication outlook and key takeaways
  • Fig. 31 U.S. neurology clinical trials market: indication movement analysis
  • Fig. 32 Alzheimer's disease market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Depression (MDD) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Parkinson's Disease (PD) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Epilepsy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Stroke market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Traumatic Brain Injury (TBI) Market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Amyotrophic Lateral Sclerosis (ALS) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Huntington's disease market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Muscle Regeneration Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 U.S. neurology clinical trials market: Indication by study design outlook and key takeaways
  • Fig. 43 U.S. neurology clinical trials market: Indication by study design movement analysis
  • Fig. 44 Alzheimer's disease interventional market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Alzheimer's disease observational market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Alzheimer's disease expanded access market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Depression (MDD) interventional market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Depression (MDD) observational market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Depression (MDD) expanded access market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 Parkinson's Disease (PD) interventional market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Parkinson's Disease (PD) observational market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Parkinson's Disease (PD) expanded access market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Epilepsy interventional market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Epilepsy observational market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Epilepsy expanded access market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 Stroke interventional market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Stroke observational market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 Stroke expanded access market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Traumatic Brain Injury (TBI) interventional market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 Traumatic Brain Injury (TBI) observational market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Traumatic Brain Injury (TBI) expanded access market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Amyotrophic Lateral Sclerosis (ALS) interventional market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Amyotrophic Lateral Sclerosis (ALS) observational market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Amyotrophic Lateral Sclerosis (ALS) expanded access market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 Huntington's disease interventional market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 Huntington's disease observational market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 Huntington's disease expanded access market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Muscle regeneration interventional market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 Muscle regeneration observational market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Muscle regeneration expanded access market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 Others interventional market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Others observational market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 73 Others expanded access market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 U.S. neurology clinical trials market: value chain design outlook and key takeaways
  • Fig. 75 U.S. neurology clinical trials market: value chain movement analysis
  • Fig. 76 In-house market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 CROs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 Investigator sites/clinical sites market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 79 Key company categorization
  • Fig. 80 Service heat map analysis
  • Fig. 81 Strategic framework